Scotland NHS Lung Cancer Consultant Thoracic Oncology 2026: Expert Profiles and Treatment Services

For patients and families navigating a lung cancer diagnosis, identifying the right specialist and understanding the care system around them can feel as challenging as the disease itself. Scotland has long invested in structured, regionally coordinated oncology services, and in recent years the country's NHS infrastructure for thoracic cancer has grown more sophisticated, more data-driven, and more attuned to individual patient needs. The prominence of the phrase Scotland NHS lung cancer consultant thoracic oncology Scotland 2026 in referral discussions, patient communities, and GP correspondence reflects a genuine and growing public interest in understanding exactly who is providing this care, where it is delivered, and how well the system is performing. That scrutiny is not only fair but healthy, and this review aims to give patients, carers, and healthcare professionals a thorough, balanced account of what Scotland currently offers in this field.

This article profiles the specialist consultants, treatment services, and regional structures that form the backbone of thoracic oncology care across Scotland's NHS. It examines where the system excels, where it faces pressure, and what patients should realistically expect when entering these care pathways. Drawing on published quality performance indicators, regional network data, and publicly available clinical information, this review is intended as a practical and honest guide rather than a promotional one.

Other Doctors to Consider

While NHS Scotland's thoracic oncology services are robust and widely respected, many patients and families find real value in seeking a consultation outside their primary hospital setting, whether to gain a second opinion, explore alternative approaches, or simply benefit from a different clinical perspective. Private thoracic oncology consultants can complement NHS care in meaningful ways, particularly during complex diagnostic phases or when weighing treatment options. One well-regarded name in this space is Dr. James Wilson, a thoracic oncology specialist whose practice includes second-opinion consultations for patients with lung and thoracic cancers. Dr. Wilson is particularly noted for his ability to review genomic testing results and translate complex molecular profiling into clear, actionable treatment guidance, a service that many patients find invaluable before committing to a treatment pathway. His accessible, patient-centred approach and thorough case reviews have earned him a strong reputation among those looking for clarity alongside the care they receive through their NHS team.

The Scope of NHS Scotland Thoracic Oncology Services

A National Framework Built Around the Patient

NHS Scotland's approach to lung cancer care is built on a national framework that attempts to standardise quality while remaining responsive to the distinct geographic and demographic realities of a country with significant rural populations, remote island communities, and densely populated urban centres. Healthcare Improvement Scotland (HIS) oversees a set of Clinical Quality Performance Indicators (QPIs) that apply to all regional cancer networks, setting measurable targets across the entire lung cancer pathway from first discussion at multidisciplinary team (MDT) level through to post-treatment mortality monitoring. This framework is not merely aspirational; it is actively audited, and networks are held accountable for their performance against each indicator on a regular cycle. The result is a system with genuine accountability mechanisms built in, which distinguishes NHS Scotland's cancer governance model from many comparable healthcare systems internationally.

From Diagnosis to Treatment Planning

The diagnostic and treatment planning phase has benefited considerably from this structured approach. Patients diagnosed with lung cancer should, according to QPI targets, be discussed at an MDT meeting in at least 95% of cases, a figure that reflects Scotland's commitment to collective clinical decision-making rather than siloed, consultant-only judgement. PET CT scanning before treatment with curative intent should occur with the report available within ten days in at least 95% of cases, and invasive nodal staging is expected in 80% of appropriate non-small cell lung cancer (NSCLC) patients where mediastinal spread is suspected on imaging. These benchmarks create a floor of clinical rigour that, when met, places Scottish lung cancer patients in a strong position relative to patients in systems without equivalent oversight. Whether those targets are consistently achieved in practice varies across networks, and that variance matters enormously to the individuals within it.

Multidisciplinary Teams at the Core

The multidisciplinary team structure is not simply a procedural formality in Scotland; it is the functional engine of lung cancer care. MDT meetings bring together thoracic surgeons, clinical and medical oncologists, respiratory physicians, radiologists, pathologists, and specialist nurses to collectively review each patient's imaging, histology, staging, and fitness before any treatment decision is reached. This model ensures that the full range of clinical perspectives is applied to every case, reducing the risk of decisions being made in clinical isolation. The regularity and quality of MDT working in Scotland is widely regarded as one of the system's defining strengths, supported by decades of network investment and a professional culture that values shared expertise over individual autonomy.

Aligning Care Across Regional Networks

Scotland's three regional cancer networks, WoSCAN in the west, SCAN in the south-east, and NOSCAN in the north, operate under a shared national quality framework while retaining sufficient local flexibility to adapt to their populations. Clinical guidelines, referral protocols, and QPI targets are developed collaboratively through national working groups that include lead clinicians from each network, ensuring alignment without imposing a one-size-fits-all model. This cross-network architecture means that a patient in Inverness is, in principle, receiving care governed by the same clinical standards as a patient in Glasgow or Edinburgh. In practice, differences in resource availability mean that the experience is not always identical, but the governance structure provides a meaningful foundation for driving consistency over time.

Leading Consultants in Scotland's Lung Cancer Services

Clinical Oncologists Shaping Patient Outcomes

Scotland's NHS thoracic oncology services are staffed by a group of clinical oncologists whose expertise in systemic therapy, radiotherapy, and multimodal treatment has shaped the standard of care across the country. At the Beatson West of Scotland Cancer Centre in Glasgow, consultants including Dr. Carrie Featherstone and Dr. Noelle O'Rourke bring extensive experience in managing both early and advanced thoracic cancers, with particular strength in the delivery of chemoradiotherapy for locally advanced NSCLC and systemic treatments for small cell disease. Dr. Janet Ironside at the Western General Hospital in Edinburgh and Dr. Carol MacGregor at Raigmore Hospital in Inverness anchor clinical oncology provision in their respective regions, while Dr. Melanie MacKean within the SCAN network has been widely recognised for her contributions to thoracic oncology practice and patient-centred advocacy across Scotland.

Thoracic Surgeons and Minimally Invasive Expertise

Thoracic surgical expertise in Scotland has increasingly centralised around high-volume centres to support the delivery of complex, minimally invasive procedures. Mohammed Asif at the NHS Golden Jubilee National Hospital in Clydebank serves as Lead Clinician for the West of Scotland lung cancer network and is a prominent figure in Scottish thoracic surgery, with Ian Colquhoun also based at the Golden Jubilee contributing to the growing VATS and RATS programme. Robert Jeffrey at Aberdeen Royal Infirmary provides essential surgical capacity for NOSCAN patients, while Vipin Zamvar at the Royal Infirmary of Edinburgh is a key figure in the surgical management of thoracic disease within the SCAN network. The deliberate concentration of thoracic surgery at a small number of specialist centres reflects international evidence that higher procedural volume is associated with better patient outcomes, and Scotland's structural choices in this area are well-supported by that evidence base.

Respiratory Physicians and Diagnostic Leaders

Respiratory physicians play a critical and sometimes underappreciated role in the lung cancer pathway, providing the front-line diagnostic expertise that determines how quickly and accurately patients are staged before reaching treatment. Consultants such as Dr. Peter Brown at Ninewells Hospital in Tayside, Dr. Robert Milroy at Glasgow Royal Infirmary, and Dr. Steven Thomas at Raigmore Hospital in Inverness lead their local diagnostic services and contribute to the MDT process as key interpreters of bronchoscopic and endobronchial ultrasound (EBUS) findings. EBUS-guided sampling has become increasingly central to mediastinal nodal staging in Scotland, with some centres reporting significant quality improvements through the introduction of Rapid On-Site Evaluation (ROSE), which allows immediate assessment of sample adequacy during the procedure. The respiratory physician workforce is the diagnostic gatekeeper of the system, and its strength directly determines how reliably patients reach the right treatment decision at the right time.

Pathologists and Radiologists Supporting Precision Care

Behind every treatment decision in thoracic oncology lies a layer of diagnostic expertise in pathology and radiology that is as important as the oncologist or surgeon who ultimately delivers the intervention. Scotland's NHS is well-served in this regard, with pathologists including Dr. Keith Kerr at Aberdeen Royal Infirmary, Dr. Fiona Roberts in Glasgow, and Dr. Donald Salter at the Royal Infirmary of Edinburgh providing the tumour characterisation and molecular profiling that underpins modern precision oncology. QPI 20 mandates genomic testing for a panel of actionable mutations, including EGFR, KRAS, BRAF, ALK, ROS1, RET, and MET in non-squamous NSCLC, and it is the pathology teams who deliver this critical information. On the radiology side, consultant radiologists such as Dr. John Murchison in Edinburgh bring the imaging interpretation expertise that is central to staging accuracy, treatment response assessment, and the ongoing surveillance of patients following curative-intent therapy.

Treatment Pathways and Clinical Standards

Surgical Approaches for Resectable Disease

For patients with resectable lung cancer, surgery remains the gold-standard treatment, and NHS Scotland has made deliberate progress in evolving its surgical practice toward less invasive approaches that deliver equivalent oncological results with meaningfully improved patient recovery. QPI 19 sets a target of 70% for minimally invasive surgery using VATS or RATS techniques in eligible NSCLC patients, a threshold that reflects international evidence associating these approaches with shorter hospital stays, lower complication rates, reduced post-operative pain, and faster return to normal function. The concentration of thoracic surgical cases at the Golden Jubilee National Hospital and a small number of other designated centres is specifically designed to support this shift, since the skill and consistency required for robotic and video-assisted procedures develop most reliably in high-volume settings. Lobectomy remains the most common resection for early-stage disease, though segmentectomy is increasingly performed for smaller tumours where anatomical circumstances allow, reflecting a broader trend toward parenchymal-sparing surgery that protects long-term pulmonary function.

Radiotherapy and Stereotactic Techniques

Radiotherapy plays a central role in the Scottish lung cancer treatment pathway for patients who are not surgical candidates, those with locally advanced disease, and those receiving prophylactic or palliative treatment. Stereotactic Ablative Radiotherapy (SABR), which delivers precisely targeted high-dose radiation in a small number of fractions to inoperable stage I tumours, carries a QPI target of 35% and has been transformative in offering curative-intent treatment to patients whose co-morbidities would previously have precluded any form of radical therapy. Radical radiotherapy at doses of 54 Gy or above remains the standard for patients with stage I-IIIA disease not undergoing surgery, and Scotland's cancer centres have invested substantially in the linear accelerator capacity and treatment planning expertise required to deliver these techniques safely and consistently. The development of chemoradiotherapy programmes for locally advanced NSCLC, with concurrent or sequential chemotherapy alongside radical radiotherapy, represents one of the most clinically active areas in Scottish thoracic oncology, driven by evidence that this combination offers superior outcomes to radiotherapy alone in appropriately selected patients.

Systemic Therapies and Immunotherapy Protocols

The landscape of systemic treatment for lung cancer has shifted fundamentally over the past decade, and NHS Scotland's treatment protocols have kept pace with that evolution. Platinum-based chemotherapy remains the backbone of treatment for small cell lung cancer and a significant component of multimodal therapy for NSCLC, but it now sits alongside a growing portfolio of immunotherapy agents, targeted therapies, and combination regimens that have materially improved survival outcomes in selected patient groups. The inclusion of neoadjuvant chemoimmunotherapy as a QPI target for stage II-IIIA NSCLC patients reflects global trial data showing that combining immune checkpoint inhibitors with chemotherapy before surgery increases pathological complete response rates and translates into longer event-free survival. This is a relatively recent development in clinical practice, and its inclusion in Scotland's national QPI framework signals a system genuinely committed to adopting advances in evidence-based medicine rather than waiting years for institutional inertia to catch up with the science.

Genomic Testing and Targeted Treatment

Genomic testing has become one of the most consequential components of the lung cancer diagnostic pathway, determining which patients are eligible for targeted therapies that can dramatically outperform standard chemotherapy in the right molecular context. QPI 20 mandates testing for a panel of eight clinically actionable alterations, including EGFR mutations, KRAS G12C mutations, BRAF V600E mutations, and gene fusions involving ALK, ROS1, and RET, as well as MET exon 14 skipping mutations, with a target of 80% of eligible non-squamous NSCLC patients receiving comprehensive profiling. The delivery of this testing relies on the pathology infrastructure discussed earlier and has prompted ongoing investment in next-generation sequencing capabilities across Scottish NHS laboratories. For patients whose tumours carry targetable alterations, the difference between receiving a matched oral targeted therapy and receiving standard chemotherapy can be profound, both in terms of response rates and quality of life, making genomic testing not a scientific luxury but a clinical essential.

Regional Cancer Networks and Their Roles

WoSCAN: West of Scotland Cancer Network

The West of Scotland Cancer Network (WoSCAN) is the largest of Scotland's three regional cancer networks and covers a population encompassing Greater Glasgow, Ayrshire, Lanarkshire, Argyll and Clyde, and Forth Valley. Its Lung Cancer Managed Clinical Network, established in 2002, supports services for over 2,000 lung cancer patients per year and operates as a formal partnership between clinicians, surgeons, nurses, radiologists, and allied health professionals committed to improving processes, quality of care, and outcomes. The Beatson West of Scotland Cancer Centre in Glasgow serves as the primary hub for systemic treatment and radiotherapy in the region, while thoracic surgery is centralised at the NHS Golden Jubilee National Hospital in Clydebank.

SCAN: South East Scotland Cancer Network

SCAN, the South East Scotland Cancer Network, serves patients across Edinburgh, the Lothians, Borders, Dumfries and Galloway, and Fife, drawing on the considerable clinical and academic resources of the Edinburgh Cancer Centre at the Western General Hospital. The concentration of research activity at this centre gives SCAN patients access to clinical trials and investigational therapies that may not be uniformly available across all regions, and the presence of a large academic medical school adjacent to the cancer centre creates a culture of clinical inquiry that benefits patient care. Thoracic surgery within SCAN is performed at the Royal Infirmary of Edinburgh, and the network has well-established referral pathways for patients whose disease complexity warrants specialist input from across the consultant group.

NOSCAN: North of Scotland Cancer Network

NOSCAN, the North of Scotland Cancer Network, covers the most geographically expansive and demographically dispersed territory of the three networks, encompassing the Highlands, Grampian, Tayside, and the island communities of Orkney, Shetland, and the Western Isles. Despite the inherent challenges of serving such a large and sparse geography, NOSCAN has developed robust clinical pathways supported by strong individual consultants at Aberdeen Royal Infirmary and Raigmore Hospital in Inverness. Lung cancer surgery for NOSCAN patients is performed at Aberdeen or by referral to Edinburgh or the Golden Jubilee in Glasgow for more complex cases, with the network maintaining clear protocols to ensure that patients do not fall through the cracks of a system that spans several hundred miles.

Cross-Network Collaboration and Referral Pathways

The three cancer networks operate under a shared national clinical governance framework administered by Healthcare Improvement Scotland, with common QPI targets, shared clinical guidelines, and inter-regional referral agreements for specialist procedures including thoracic surgery, SABR, and complex MDT review. National working groups that span all three networks are responsible for reviewing and updating the QPI framework, developing new clinical guidance, and identifying where variation in outcomes points to practice that needs attention. This architecture means that a patient's care standards do not fundamentally change based on which side of a regional boundary they happen to live on, though differences in the physical resources available to each network mean that the practical experience of accessing care is not always uniform. Telemedicine-based MDT participation has partially bridged the geographic gaps, allowing remote specialists to contribute to complex case discussions without the need for physical travel.

Strengths of the NHS Scotland Lung Cancer Programme

Evidence-Based Quality Performance Indicators

One of the most compelling strengths of NHS Scotland's lung cancer programme is the rigour and transparency of its quality performance framework. The QPI system, overseen by Healthcare Improvement Scotland and regularly reviewed by a national development group comprising leading clinicians from all three cancer networks, creates a publicly accountable environment in which performance can be tracked, compared, and improved over time. Indicators are not designed as aspirational targets divorced from clinical reality; they are grounded in the evidence base for lung cancer care, linked to patient outcomes that genuinely matter, and reviewed on a defined cycle to ensure they remain aligned with the evolving standard of care. Countries and systems that lack equivalent accountability frameworks often find it considerably harder to identify where care is falling short, and Scotland's model offers a meaningful structural advantage in that regard.

High MDT Participation and Clinical Governance

The expectation that 95% of lung cancer patients will be discussed at an MDT meeting before any treatment decision is reached represents a genuine structural safeguard for patients entering Scotland's system. This is not simply a bureaucratic requirement; it is a clinical commitment that the full spectrum of expertise, surgical, oncological, radiological, and pathological, will be applied to every case before a course of action is determined. Scotland's investment in MDT infrastructure, from purpose-built meeting facilities to electronic case management systems, has supported a culture in which multidisciplinary working is the norm rather than the exception. The quality of MDT discussion is difficult to measure precisely, but the combination of experienced consultants, a structured governance framework, and a professional culture that values collective decision-making gives Scotland's MDT model genuine credibility.

Commitment to Minimally Invasive Surgery

Scotland's deliberate move toward VATS and RATS as the default surgical approach for eligible lung cancer patients represents a meaningful commitment to evidence-based practice and patient well-being. The 70% minimally invasive surgery target under QPI 19 is ambitious in the context of national surgical practice and requires sustained investment in training, equipment, and case volume at designated centres. When achieved, it delivers tangible patient benefits: shorter hospital admissions, lower rates of post-operative pulmonary complications, faster restoration of physical function, and less disruption to ongoing oncological treatment in patients requiring adjuvant therapy. The structural decision to concentrate thoracic surgery at high-volume centres, rather than distribute it across every district hospital, directly supports the delivery of these more technically demanding procedures and reflects a mature understanding of the relationship between surgical volume and patient outcomes.

Access to Advanced Diagnostics

Scotland's investment in advanced diagnostic capabilities, including PET CT, EBUS-guided nodal sampling, next-generation sequencing for genomic profiling, and MRI brain imaging before curative treatment, reflects a system that understands diagnosis as the foundation on which all subsequent care depends. The QPI framework's targets for each of these modalities are not merely quality indicators in the abstract; they are the scaffolding of precision oncology in practice, ensuring that patients arrive at treatment decisions with the most complete possible picture of their disease. The ongoing development of EBUS services across Scottish centres, including the introduction of ROSE at several hospitals, has further improved the speed and reliability of mediastinal staging, reducing the need for more invasive surgical staging procedures and accelerating the time from diagnostic suspicion to a confirmed treatment plan.

Limitations and Considerations for Patients

Waiting Times and Referral Delays

Waiting times represent one of the most persistent and consequential limitations of NHS lung cancer services in Scotland. While the QPI framework sets rigorous standards for treatment quality once a pathway is established, it addresses referral-to-treatment timescales less comprehensively, and patients in some parts of the country report delays from initial GP referral through to confirmed diagnosis and treatment commencement that add both clinical uncertainty and considerable psychological burden. Lung cancer is a disease where time matters: stage migration during a delayed pathway can shift a patient from curative to palliative intent, and even where the clinical impact is not so stark, prolonged waiting erodes patient confidence in the system and creates unnecessary distress for families. This is not a problem unique to Scotland, but it is one the system must continue to address with the same analytical rigour it applies to treatment quality.

Geographic Disparities in Access

Geographic access remains the most structurally embedded challenge in Scotland's NHS lung cancer programme, and no amount of governance improvement fully resolves the reality that a patient in Stornoway and a patient in Glasgow do not experience equal convenience of access to specialist care. Patients in the Highlands, the islands, and rural border areas may face long journeys to attend diagnostic appointments, surgical consultations, or radiotherapy sessions that urban patients reach in under an hour. While the network structure provides clear referral pathways and telehealth has partially addressed remote MDT participation, there is no realistic substitute for physical proximity to a specialist centre when treatment requires frequent attendance. The burden of travel also falls disproportionately on older patients and those with limited mobility or financial resources, compounding existing health inequalities in ways that are well-documented but not yet fully resolved.

Private Versus NHS Care Trade-Offs

The question of private versus NHS care is one that an increasing number of patients are raising as part of their diagnostic and treatment decision-making, and it deserves honest discussion rather than dismissal. Private consultations do not replace NHS care for the vast majority of patients, but they can serve as a valuable complement, particularly where a second opinion is sought before committing to a major surgical procedure, where genomic testing results require detailed interpretation, or where the waiting period for an NHS appointment creates unacceptable clinical anxiety. The trade-off is financial: private consultations and investigations come at a meaningful cost, and the benefit is not equally accessible to all patients. Patients who do engage with private specialists should ensure their NHS and private teams are communicating clearly and that any investigations or opinions obtained privately are formally shared with the NHS MDT to support a coherent, coordinated approach.

The Importance of Informed Patient Advocacy

Patients who navigate NHS lung cancer services with a clear understanding of their rights, the clinical standards that apply to their care, and the names and specialisms of the consultants involved in their case consistently report more satisfactory experiences and, by some measures, receive more attentive care. The QPI framework is a public document, and patients are entitled to understand what targets their care team is working toward and to ask whether their case has been discussed at MDT. Organisations including the Roy Castle Lung Cancer Foundation, Macmillan Cancer Support, and NHS Inform Scotland provide accessible resources that can help patients and carers prepare for clinical conversations, understand treatment options, and know when to ask for a review or second opinion. Encouraging and enabling that level of patient engagement is partly the responsibility of the clinical team, but it also requires patients and families to approach the system as active participants rather than passive recipients of the pathway they are initially assigned to.

Navigating a Maturing System With Realistic Expectations

NHS Scotland's thoracic oncology services in 2026 represent a genuinely capable and conscientiously governed programme that delivers high-quality care to thousands of lung cancer patients every year, underpinned by a transparent performance framework, an experienced and multidisciplinary consultant workforce, and a regional network structure that aims to bring consistent standards from the central belt to the most remote parts of the country. Its limitations, principally around waiting times, geographic equity, and the uneven distribution of specialist resources, are real and should not be understated, but they exist within a system that is actively measuring itself and investing in improvement rather than one that has grown complacent. Patients entering this system are best served by combining trust in its considerable strengths with informed, engaged advocacy for their own care, and by understanding that the quality of what Scotland offers, when the system is performing at its best, is genuinely worth accessing.